Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Faes FarmaXMAD:FAE -1.03%93 5-Day RSI is 24.54 as of Jul. 21, 2026. GuruFocus rates XMAD:FAE with a GF Score™ of 93/100 and a GF Value™ of €5.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,040 Drug Manufacturers companies, Faes Farma ranks better than 88.56% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-21), Faes Farma's 5-Day RSI is 24.54.
The industry rank for Faes Farma's 5-Day RSI or its related term are showing as below:
XMAD:FAE's 5-Day RSI is ranked better than 88.56% of 1040
companies
in the Drug Manufacturers industry
Industry Median: 44.615
vs XMAD:FAE: 24.54
Faes Farma (XMAD:FAE) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Faes Farma 5-Day RSI Related Terms
XMAD:FAE vs ZTS, UTHR, VTRS: 5-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faes Farma 5-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Faes Farma's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Faes Farma's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faes Farma (XMAD:FAE) has a 5-Day RSI of 24.54 as of Jul. 21, 2026. According to the industry distribution chart, Faes Farma ranks #119 out of 1040 companies in the Drug Manufacturers industry, placing it in the top 11.4%.
Is Faes Farma's 5-Day RSI too high?
Faes Farma's current 5-Day RSI is 24.54. The Drug Manufacturers industry median 5-Day RSI is 44.62. Faes Farma's value of 24.54 is 45% below this industry median. Based on the distribution chart, Faes Farma ranks #119 out of 1040 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Faes Farma has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's 5-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Faes Farma ranks #119 out of 1040 companies for 5-Day RSI. This places Faes Farma in the top 11% of its industry — outperforming the majority of peers. The industry median 5-Day RSI is 44.62. Faes Farma's value of 24.54 is 45% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Drug Manufacturers company?
The median 5-Day RSI among Drug Manufacturers companies is 44.62, based on 1,040 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Faes Farma's current 5-Day RSI of 24.54 is 45% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 5-Day RSI is 44.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faes Farma's current 5-Day RSI is 24.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.18, compared to a current price of €4.35 — trading 16.1% below its estimated fair value. The current 5-Day RSI is 24.54 and 45% below the Drug Manufacturers industry median of 44.62. Faes Farma's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current 5-Day RSI is 24.54 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Faes Farma (XMAD:FAE) Overvalued in 2026?
Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued.
The current stock price of €4.35 is trading 16.1% below its estimated GF Value™ of €5.18.
GuruFocus considers Faes Farma to be Modestly Undervalued.
Key valuation signals for XMAD:FAE:
5-Day RSI: 24.54
GF Value™: €5.18 vs. price of €4.35 (16.1% below fair value)
Industry Position: 45% below the Drug Manufacturers median (#119 of 1040)
No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
93GF Score
Get the complete analysis for XMAD:FAE
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:FAE has been successfully added to your 
